January 08, 2015
A Delaware federal judge has thrown out generics maker Perrigo Co.'s counterclaims alleging that AbbVie Inc. patents for the testosterone replacement gel Androgel are unenforceable due to inequitable conduct, calling the lengthy allegations "impenetrable" and likening them to "garbage."